XRAY is in a sustained downtrend over the past year, with a 1-year price change of -26.23% and currently trading at $12.26, which is 72% of its 52-week range (low $9.41, high $17.09). The stock is well below its 52-week high, indicating persistent bearish pressure, though it has recently bounced from the low end of the range, suggesting a potential bottoming process. The 52-week low of $9.41 was tested in May 2026, and the current price is 30% above that level, reflecting a recovery attempt but still far from the highs. Short-term momentum has turned sharply positive, with a 1-month price change of +22.11% and a 3-month change of +4.70%, contrasting with the 1-year decline. This divergence suggests a potential trend reversal or mean reversion rally, as the stock has outperformed the S&P 500 by 18.04% over the past month (relative strength 1m = 18.04%). However, the 3-month relative strength remains negative at -6.41%, indicating that the longer-term trend is still bearish. The stock's beta of 0.894 implies it is slightly less volatile than the market, which may provide some downside protection but also limits upside participation in strong market rallies. Key support lies at the 52-week low of $9.41, a break below which would signal further downside and a potential test of single-digit levels. Resistance is at the 52-week high of $17.09, and a breakout above that level would indicate a major trend reversal. The recent rally from $9.82 in mid-May to $12.26 shows building momentum, but the stock remains in a downtrend until it can reclaim the $14-15 area.

Revenue has shown modest growth, with Q4 2025 revenue of $961 million, up 6.19% year-over-year from $905 million in Q4 2024. However, the multi-quarter trend reveals deceleration: Q1 2025 revenue was $879 million, Q2 $936 million, Q3 $904 million, and Q4 $961 million, indicating choppy performance. The Technologies & Equipment segment contributed $548 million and Consumables $430 million in Q4, with equipment driving growth while consumables remain stable. The overall growth trajectory is weak, and the company faces headwinds from competitive pressures and end-market softness, making the investment case dependent on successful product launches and cost restructuring. Profitability has deteriorated sharply, with net income of -$146 million in Q4 2025 versus -$430 million in Q4 2024, though still deeply negative. Gross margin improved to 46.1% from 49.3% a year ago, but operating margin turned negative at -3.3% (EBITDA ratio -3.3%) compared to -46.3% in Q4 2024, reflecting significant impairment charges. The company has been unprofitable for four consecutive quarters, with net losses totaling -$598 million over the trailing twelve months. The trajectory toward profitability remains uncertain, as restructuring costs and goodwill impairments continue to weigh on earnings. The balance sheet shows elevated leverage, with a debt-to-equity ratio of 1.84 and total debt of approximately $2.1 billion against equity of $1.1 billion. Free cash flow was $60 million in Q4 2025, improving from $36 million a year ago, but the TTM free cash flow of $104 million provides only modest coverage. The current ratio of 1.51 indicates adequate liquidity, but the high debt burden and negative ROE of -44.6% signal financial risk. The company's ability to generate sufficient cash to service debt and fund operations without external financing is a key concern.